Markets:

Overview

News

Currencies

International

Treasuries

State Street SPDR S&P Biotech ETF (NY:XBI)

129.71 +2.92 (+2.30%)

Streaming Delayed Price Updated: 9:54 AM EDT, May 20, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about State Street SPDR S&P Biotech ETF

< Previous 1 2 3 4 5 6 7 8 9

...

15 16 Next >

Vinay Prasad's Appointment To FDA's CBER Triggers Questions Over Future Of Cell And Gene Therapy Regulation ↗

May 07, 2025

FDA names Vinay Prasad to lead CBER, raising questions over biologics oversight and triggering biotech stock losses and analyst concerns.

Via Benzinga

Capricor Therapeutics Stock Tumbles After FDA Confirms Intent To Hold Advisory Committee Meet For Deramiocel Approval: But Retail’s Optimistic ↗

May 05, 2025

The U.S. FDA stated that its review committee has identified no significant deficiencies and is on track to make a decision on the application by its deadline of the end of August.

Via Stocktwits

Topics Economy Government

Large Cap Biopharmaceutical Update: Mixed Performance As Tariffs Loom ↗

April 28, 2025

Biopharma stocks rally along with many of our SMID cap trades. The market situation with pharmaceuticals is even more complicated because we started off with legislation (the IRA) trying to curb rising...

Via Talk Markets

Topics ETFs Stocks / Equities

Summit Therapeutics Stock Slumps After Partner Akeso Gets FDA Nod For Cancer Drug: Retail’s Optimistic ↗

April 25, 2025

The company’s lead candidate, ivonescimab, aimed at treating certain cancers, was discovered by Akeso and is currently in multiple late-stage clinical trials.

Via Stocktwits

Topics Artificial Intelligence

Immunovant Announces Roivant President Eric Venker As New CEO: Retail’s Elated ↗

April 21, 2025

Immunovant stated that these changes are part of its parent entity, Roivant, increasing operational involvement and strategic oversight of the company.

Via Stocktwits

Topics Government Retirement Stocks

uniQure Stock Jumps On FDA’s Breakthrough Therapy Designation For Investigational Gene Therapy: Retail’s Optimistic ↗

April 17, 2025

The new designation is in addition to the existing Regenerative Medicine Advanced Therapy, Orphan Drug, and Fast Track designations granted to AMT-130.

Via Stocktwits

Topics Bankruptcy

Why Summit Therapeutics Rallied Double Digits Today on Another Down day for the Markets ↗

April 10, 2025

Via The Motley Fool

Topics ETFs

Is It A Good Time To Trade Small Cap Biotech Stocks? - 3 Steps To Consider ↗

April 07, 2025

Large cap healthcare stocks have outperformed other sectors during the 2025 Tariff induced sell-off but they still have risks as one can see by Friday’s 5% decline.

Via Talk Markets

Topics ETFs Stocks / Equities

Biotech Weakness Ahead? ↗

April 02, 2025

Out of 50,000 posts, I’m not sure I’ve ever mentioned the sector fund XBI before, but here we are. It seems to me that this fund, representing the biotech sector, is in for some serious skidding.

Via Talk Markets

Topics ETFs

Biotech Stocks Dive After Trump Tacks On 20% European Tariff. Why AbbVie, Merck Could Be Exposed. ↗

April 02, 2025

It's unclear whether pharmaceutical goods could be exempt from tariffs. A number of drugmakers manufacture ingredients abroad.

Via Investor's Business Daily

Topics Economy Government World Trade

Retail Traders Mostly Bullish On Biotech Stocks Amid Blow From RFK Jr. Purge On Health Agencies ↗

April 02, 2025

The sector's recent slide follows Peter Marks' resignation last week as the Food and Drug Administration's top vaccine regulator following a clash with Kennedy.

Via Stocktwits

Topics ETFs Government

Biotech Stocks Take Another Beating As 'Chaos' Reigns At FDA With Reports Of Mass Firings ↗

April 01, 2025

Reports of mass firings include another high-profile official as Robert F. Kennedy Jr. and Marty Makary take up their new roles.

Via Investor's Business Daily

Topics Workforce

Moderna, Novavax Shares Are Tumbling Monday: What's Going On? ↗

March 31, 2025

Vaccine stocks are trading lower Monday following a shakeup at the U.S. Food and Drug Administration.

Via Benzinga

Moderna, Vaxcyte, Novavax Hammered After Key FDA Official Peter Marks Resigns ↗

March 31, 2025

Peter Marks heads up the department in charge of reviewing vaccines, genetic medicines and cell therapies.

Via Investor's Business Daily

Soleno Therapeutics Stock Rockets 34% Pre-Market After FDA Approves Prader-Willi Syndrome Drug: Retail Sentiment Peaks ↗

March 27, 2025

The company expects the drug, the first approved therapy to address hyperphagia in PWS patients, to be available in the U.S. starting April 2025.

Via Stocktwits

Sarepta Therapeutics Stock Has A Nightmarish Week After DMD Patient Death, But Retail And Analysts Aren't Giving Up ↗

March 21, 2025

Jefferies acknowledged acute liver failure could signal a new safety risk but maintained that the high unmet need for DMD treatments supports the bull case.

Via Stocktwits

Capricor Therapeutics Stock Surges After Q4 Results Beat Estimates: Retail Gets More Bullish ↗

March 20, 2025

The company said its available cash, cash equivalents, and marketable securities will be sufficient to cover the expenses and capital requirements into 2027.

Via Stocktwits

Altimmune Shares Sink This Year, But Retail Traders See A Buyout On The Horizon ↗

March 19, 2025

A Betaville report suggested Altimmune has begun a strategic review with an adviser, with speculation that three major pharmaceutical firms may be involved.

Via Stocktwits

Sangamo Therapeutics Retail Traders Keep The Faith Even As Stock Slides After-Hours On Q4 Miss ↗

March 18, 2025

Several optimistic users expressed confidence in the company securing a third potential agreement with a major pharma for its adeno-associated virus (AAV) capsid, STAC-BBB.

Via Stocktwits

Healthcare Stocks Doing Well But SMID Biotech Looking A Little Frazzled ↗

March 10, 2025

Small caps took another step down this past week as geopolitical events dampened sentiment.

Via Talk Markets

Topics ETFs Stocks / Equities

SpringWorks Therapeutics Leads Biotech Pack In Weekly Retail Follower Surge: What's Fueling Interest? ↗

March 10, 2025

Investor attention is now on whether Merck will confirm a formal offer as speculation over a potential acquisition continues dominating discussions around the stock.

Via Stocktwits

Healthcare Sector Trying To Bounce Back ↗

March 09, 2025

I often discuss highly rated stocks that are part of highly rated sectors. Thus, this time is a departure from the norm. Let's dive into the data for the healthcare sector.

Via Talk Markets

Topics ETFs Stocks / Equities

Capricor Therapeutics’ Retail Chatter Explodes On Stocktwits After FDA Grants Priority Review For DMD Therapy ↗

March 04, 2025

The health agency has accepted Capricor's Biologics License Application for full approval of deramiocel as a treatment for Duchenne muscular dystrophy cardiomyopathy.

Via Stocktwits

Is It Time To Shift Focus To Beaten-Down Healthcare Stocks As Volatility Soars? ↗

March 04, 2025

Healthcare performed terribly in 2023 and 2024, falling while the market was soaring. Year-to-date, the sector has outperformed. Is it time to focus on the stocks and ETFs of this low-Beta sector as...

Via Talk Markets

Topics ETFs Stocks / Equities

Biotech Rally Coming In Weeks Ahead? ↗

March 04, 2025

Large cap biopharma and MedTech stocks are leading the healthcare sector higher.

Via Talk Markets

Topics ETFs Stocks / Equities

Emergent BioSolutions Stock Sinks As Q4 Revenue Plunges 30%, But Retail Clings To Profit Swing ↗

March 04, 2025

For the first quarter, Emergent forecasted revenue in the range of $200 million to $240 million, lower than an analyst estimate of $279 million.

Via Stocktwits

Adma Biologics' Retail Traders Eye Higher Open After Blowout Q4, Strong Full-Year Outlook ↗

March 03, 2025

CEO Adam Grossman highlighted a 65% year-over-year jump in total revenue and a staggering 309% increase in adjusted EBITDA for 2024.

Via Stocktwits

Retail Bets TG Therapeutics Stock Can Sustain Post-Earnings Gains Throughout The Week ↗

March 03, 2025

Annual revenue from its MS drug, Briumvi, more than tripled, with U.S. net product revenue reaching $103.6 million in the fourth quarter and $310 million for the full year.

Via Stocktwits

Altimmune Retail Buzz Heats Up On MASH Progress, FDA Nod For New Trials: Stock Jumps After Q4 Print ↗

February 27, 2025

The company plans to unveil details at its virtual R&D Day on March 13.

Via Stocktwits

MannKind Stock Surges After-Hours On Q4 Revenue Beat, Debt Reduction As Retail Investors Celebrate ‘Amazing Comeback’ ↗

February 27, 2025

The company significantly reduced its debt principal by $236 million, leaving just $36 million in remaining convertible debt, and ended 2024 with $203 million in cash, cash equivalents, and...

Via Stocktwits

< Previous 1 2 3 4 5 6 7 8 9

...

15 16 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.